Brooklyn Immunotherapeutics Inc
NASDAQ:BTX
Intrinsic Value
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BTX.
Fundamental Analysis
Balance Sheet Decomposition
Brooklyn Immunotherapeutics Inc
Brooklyn Immunotherapeutics Inc
Earnings Waterfall
Brooklyn Immunotherapeutics Inc
|
Revenue
|
5.8m
USD
|
|
Cost of Revenue
|
-2.9m
USD
|
|
Gross Profit
|
2.9m
USD
|
|
Operating Expenses
|
-8.3m
USD
|
|
Operating Income
|
-5.4m
USD
|
|
Other Expenses
|
968k
USD
|
|
Net Income
|
-4.4m
USD
|
Free Cash Flow Analysis
Brooklyn Immunotherapeutics Inc
What is Free Cash Flow?
BTX Profitability Score
Profitability Due Diligence
Brooklyn Immunotherapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Brooklyn Immunotherapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
BTX Solvency Score
Solvency Due Diligence
Brooklyn Immunotherapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Brooklyn Immunotherapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BTX Price Targets Summary
Brooklyn Immunotherapeutics Inc
Ownership
BTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BTX Price
Brooklyn Immunotherapeutics Inc
| Average Annual Return | 44.94% |
| Standard Deviation of Annual Returns | 57.83% |
| Max Drawdown | -100% |
| Market Capitalization | 549.9k USD |
| Shares Outstanding | 2 681 300 |
| Percentage of Shares Shorted | 2.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. The firm is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.
You don't have any saved screeners yet
